KP 496

Drug Profile

KP 496

Alternative Names: KP-496; KP-496DPI; KP-496NS; S-36496

Latest Information Update: 02 Jun 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kaken Pharmaceutical
  • Class Antiasthmatics; Benzoic acids
  • Mechanism of Action Leukotriene D4 receptor antagonists; Thromboxane A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Allergic rhinitis; Asthma

Most Recent Events

  • 02 Oct 2009 Kaken completes recruitment in a phase II exploratory trial in perennial Allergic rhinitis in Japan
  • 03 Aug 2007 Discontinued - Phase-II for Asthma in Japan (Inhalation)
  • 03 Aug 2007 Preclinical trials in Allergic rhinitis in Japan (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top